KLF4 and pulmonary arterial hypertension: Given that AAV1‐KLF4‐shRNA could prevent the development of CS‐induced PH, we also sought to determine whether gene knockdown of KLF4 via AAV1‐KLF4‐shRNA had therapeutic efficacy in established PAH.